NCT01818726 - Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2014

Primary Completion Date

October 17, 2016

Study Completion Date

October 17, 2016

Conditions

Aplastic Anemia

Interventions

DRUG

ICL670

ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.

DRUG

Chelation

Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).

DRUG

No chelation

Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)

Trial Locations (1)

125167

Novartis Investigative Site, Moscow